Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Pharm Res. 2015 Mar 4;32(8):2753–2763. doi: 10.1007/s11095-015-1660-z

Figure 2.

Figure 2

Gadolinium plasma concentration -time profile after IV via tail vein or IP administration of non-targeted and EGFR-targeted nanoemulsion formulations to nu/nu mice. Gadolinum dose was 0.072 mmoles/kg. n=3.